Professor Irit Ben Aharon and other Technion scientists have been awarded grants to fund their research into cancer, including the effects of chemotherapy on pregnant women and their children.

The Irish Centre for Human Rights has issued a second open letter to the University of Galway, urging it to cut ties with the Israeli Technion. The university has stated it cannot do so due to ongoing contractual obligations.

Professor Yitzhak Apeloig, former president of Technion, has passed away at the age of 81. His tenure was marked by significant academic development despite national and global challenges.

Researchers from the Technion – Israel Institute of Technology have made a significant scientific discovery in electron microscopy, providing the first direct experimental evidence for the existence of 'dark spots' that appear to move faster than the speed of light.

The Technion has been ranked 25th worldwide in AI, notably placing eighth globally for graduates who founded AI companies, surpassing institutions like Harvard despite a significantly smaller endowment.

A Technion–Haifa University project has developed a rapid AI tool that uses public architectural records to provide structural layouts to rescuers in under 30 seconds, in response to recent missile strikes.

The Technion – Israel Institute of Technology has announced the creation of a new aerospace prize, designed to recognize significant contributions from legends and trailblazers in the field. Nominations for the inaugural award will open in 2026, with the first prize to be presented in June 2027.

The Technion has been recognized as the leading institution in Europe for AI research according to the CSRankings index, also securing the 21st position globally, and is noted for its successful tech spinoffs.

Scientists from Technion-Israel have engineered nanoparticles capable of treating aggressive "triple-negative" breast cancer tumors without the need for chemotherapy or drugs, potentially offering a chemical-free treatment for the deadly disease.

Researchers from Technion and an international team have developed and validated a new AI model that can predict the benefit of chemotherapy in breast cancer patients using routine pathology samples, offering a fast and accessible alternative to genomic tests.